Prime Highlights:

• Cellbyte secures $2.75 million in seed funding to develop an AI-driven platform for faster, smarter drug launches.
• The platform aims to help pharmaceutical companies analyse large datasets and optimise pricing, market access, and launch strategies.

Key Facts:

• Traditional drug launch processes can take over a year and require extensive manual data analysis, costing hundreds of thousands of dollars.
• Cellbyte’s system can process millions of data points in minutes, reducing timelines and improving decision-making for drug launch teams.

Background

Cellbyte has raised $2.75 million in seed funding to build an AI-driven platform aimed at transforming how pharmaceutical companies launch new drugs. The company said the investment will support the development of tools that help drug launch teams analyse large datasets and design faster, more effective market strategies.

Pharmaceutical companies launch a new drug by setting prices, planning reimbursements, collecting market data, and getting regulatory approvals. These processes can take more than a year, delaying access to life-saving medicines. Companies also spend hundreds of thousands of dollars gathering and interpreting market information before a launch.

Cellbyte said its AI-native platform will significantly cut these timelines. The system can analyse millions of data points within minutes, helping teams decide the best launch order, pricing approach, and market access strategy. The company aims to replace legacy databases that currently require long manual workflows and slow decision-making.

“I’ve seen many innovations transform clinical development, but pricing and market access still rely on manual work and anecdotal evidence,” said Daniel Moreira, Cellbyte’s co-CEO and co-founder. “Generative AI is now changing that.”

Co-CEO and co-founder Felix Steinbrenner said the pharmaceutical sector is ready for faster, more efficient tools. “The industry is ready to rethink drug launch workflows and adopt higher-quality and cost-effective processes,” he said.

With this funding, Cellbyte plans to accelerate product development and bring its platform to drug developers looking to cut costs and speed up launches. The company uses AI-driven insights to help deliver medicines to patients faster and lower the financial burden on pharmaceutical teams.